908 Devices Inc. (MASS)
NASDAQ: MASS · Real-Time Price · USD
6.94
-0.13 (-1.84%)
Aug 15, 2025, 10:46 AM - Market open

Company Description

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.

Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

The company’s products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.

It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas.

The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

908 Devices Inc.
908 Devices logo
CountryUnited States
Founded2012
IPO DateDec 18, 2020
IndustryMedical Devices
SectorHealthcare
Employees246
CEOKevin Knopp

Contact Details

Address:
645 Summer Street
Boston, Massachusetts 02210
United States
Phone857 254 1500
Website908devices.com

Stock Details

Ticker SymbolMASS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001555279
CUSIP Number65443P102
ISIN NumberUS65443P1021
Employer ID45-4524096
SIC Code3829

Key Executives

NamePosition
Dr. Kevin J. Knopp Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dr. Christopher David Brown Ph.D.Co-Founder, Board Advisor and Director
Joseph H. Griffith IVChief Financial Officer and Treasurer
Michael S. Turner Esq., J.D.Chief Legal and Administrative Officer and Secretary
Barbara RussoVice President of Marketing and Corporate Communications
Don OsmerVice President of Human Resources

Latest SEC Filings

DateTypeTitle
Aug 11, 2025SCHEDULE 13GFiling
Aug 5, 202510-QQuarterly Report
Aug 5, 20258-KCurrent Report
Aug 4, 20258-KCurrent Report
Jun 16, 2025144Filing
Jun 16, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
Jun 4, 2025144Filing
May 28, 2025SDForm - SD
May 15, 2025SCHEDULE 13G/AFiling